Friday, November 11, 2016 - 07:00

AGM statement

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, is holding its Annual General Meeting ("AGM") at 10.00am today.

At the AGM, Peter Allen, Clinigen's Chairman will say:

“The year to 30 June 2016 marked the completion of our transformation into the global market leader in the management and supply of both unlicensed and clinical trial medicines.

“Alongside significant strategic progress, we delivered a strong financial performance with good levels of organic growth combining with acquisitions to increase adjusted EPS* by 25%. Trading for the current financial year remains in line with the Board’s expectations.

“At the management level, as you know, Peter George will step down as CEO after the AGM and Shaun Chilton will now take over. We are pleased Peter will continue to work with the Group as a Non-Executive Director.

“Our focus is now fixed on leveraging our global leadership positions, and we will continue to drive organic growth supported by acquisitions and the revitalisation of products.” 

*Adjusted basic earnings per share is excluding share based payment costs, non-underlying costs, amortisation and associated tax credit.

-Ends-

Contact Details

Clinigen Group plc

Tel: +44 (0) 1283 495010
Shaun Chilton, Group Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations

Numis Securities Limited

Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

Peel Hunt LLP - Joint Broker

Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden

Instinctif Partners

Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com 
Melanie Toyne-Sewell / Jayne Crook / Emma Barlow

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions:

Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

Back to News